Key learning points: diabetes and frailty in older adults
Dr David Strain outlines six key learning points from an expert consensus statement on managing diabetes and frailty, and identifies where treatment should differ from a standard approach
Tailor treatment of type 2 diabetes to improve cardiovascular outcomes
Karen Bartha discusses the Association of British Clinical Diabetologists position statement on the use of newer antidiabetic drugs in patients with cardiovascular disease
Manage diabetes and comorbidities with a joined-up strategy
Dr Umesh Dashora and colleagues from the CaReMeUK Partnership outline guidance on how to manage type 2 diabetes with cardiovascular and renal disease
Diabetes in chronic kidney disease requires practical, evidence-based care
Dr Pam Brown and Dr Colin Kenny discuss recommendations from a new international guideline on diabetes management in patients with chronic kidney disease
Type 2 diabetes: maintain glycaemic control to prevent complications
Dr Samuel Seidu and Professor Kamlesh Khunti discuss the recommendations of the Primary Care Diabetes Europe position statement on the management of type 2 diabetes
Test and reflect
Our multiple-choice questions (MCQs) are designed to help you test your knowledge and reflect on your learning after reading an article.
UK expert consensus statement on the management of older adults with diabetes
ABCD guideline on type 2 diabetes and cardiovascular outcomes
CaReMeUK guideline on the management of diabetes and comorbidities
Patient scenarios: CaReMeUK guidance on the management of diabetes and comorbidities
Patient scenarios: KDIGO guideline on diabetes and CKD
Educational resources
Deep dive on SGLT2 inhibitors with a focus on Jardiance® (empagliflozin)
This eLearning module has been commissioned and funded by the Boehringer Ingelheim and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice and Guidelines Learning. Products are discussed.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain or Northern Ireland
PC-GB-104397 April 2021
Dipeptidyl peptidase-4 inhibitors—still a major player in type 2 diabetes care
This promotional webinar has been initiated and commissioned by Boehringer Ingelheim Limited and organised in partnership with Guidelines in Practice.
View Trajenta® (linagliptin) prescribing and adverse events reporting information for:
Great Britain
Northern Ireland
PC-GB-103485 | July 2021
Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes
This working party guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd
Steglatro®▼ (Ertugliflozin)
This formulary decision guide was developed from content provided by MSD UK Ltd in a format developed by Guidelines in Practice.
View prescribing information and adverse event reporting
GB-STE-00433 | June 2021
Trurapi▼ (insulin aspart 100 units/ml)
This formulary decision guide was developed from content provided by Sanofi Ltd in a format developed by Guidelines in Practice.
View prescribing and adverse event reporting information
MAT-GB-2101070(v2.0) | Date of preparation: July 2021